Two-year results of a randomised trial comparing 4- versus 12-weekly bone-targeted agent use in patients with bone metastases from breast or castration-resistant prostate cancer
Authors:
Open Access
- 2 September 2021
- journal article
- research article
- Published by Elsevier in Journal of Bone Oncology
- Vol. 30, 100388
Abstract
No abstract availableKeywords
Funding Information
- Ottawa Hospital Foundation
- American Society of Clinical Oncology (OCREB 1-866-678-6427 Ext 6649)
- Canadian Institutes of Health Research
This publication has 26 references indexed in Scilit:
- De-Escalation of Bone-Targeted Agents for Metastatic Prostate CancerCurrent Oncology, 2016
- A randomized, double-blind, phase II, exploratory trial evaluating the palliative benefit of either continuing pamidronate or switching to zoledronic acid in patients with high-risk bone metastases from breast cancerBreast Cancer Research and Treatment, 2015
- Dosing Strategies of Bone-Targeting AgentsJAMA Internal Medicine, 2015
- Predictive factors of overall quality of life in advanced cancer patients using EORTC QLQ-C30Expert Review of Pharmacoeconomics & Outcomes Research, 2013
- Randomized Feasibility Study of De-escalated (Every 12 wk) Versus Standard (Every 3 to 4 wk) Intravenous Pamidronate in Women With Low-risk Bone Metastases From Breast CancerAmerican Journal of Clinical Oncology, 2013
- Bone-targeted agent use for bone metastases from breast cancer and prostate cancer: A patient surveyJournal of Bone Oncology, 2013
- De-escalated administration of bone-targeted agents in patients with breast and prostate cancer—A survey of Canadian oncologistsJournal of Bone Oncology, 2013
- The European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire for patients with Bone Metastases: The EORTC QLQ-BM22European Journal of Cancer, 2009
- Randomized Phase II Trial of Denosumab in Patients With Bone Metastases From Prostate Cancer, Breast Cancer, or Other Neoplasms After Intravenous BisphosphonatesJournal of Clinical Oncology, 2009
- Phase II Trial Evaluating the Palliative Benefit of Second-Line Zoledronic Acid in Breast Cancer Patients With Either a Skeletal-Related Event or Progressive Bone Metastases Despite First-Line Bisphosphonate TherapyJournal of Clinical Oncology, 2006